The Second Circuit upheld the insider trading conviction of Robert Schulman, a former patent attorney at Hunton & Williams, convicted in 2017 for tipping his investment adviser, Tibor Klein, to Pfizer’s planned acquisition of King Pharmaceuticals in 2010. Schulman appealed a decision rejecting his motion to vacate his conviction on grounds of insufficient evidence. In affirming that decision, the Second Circuit concluded that the jury was not required to credit Schulman’s testimony that he intended only to brag about his knowledge of the merger to a friend.
January 10, 2019
Second Circuit upholds insider trading conviction of former lawyer
Related by Topic
New Post
SEC settles with California resident to resolve insider trading charges
March 12, 2023
News Alert
New Post
SEC charges healthcare executive with insider trading in connection with two Rule 10b5-1 trading plans
March 6, 2023
News Alert
SEC charges private equity consultant and his close friend with insider trading
February 28, 2023
News Alert